🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementGLP-1 and menstrual irregularity — my results so far

GLP-1 and menstrual irregularity — my results so far

mike_mealprep Tue, Nov 18, 2025 at 11:39 AM 29 replies 1,414 viewsPage 1 of 6
This thread is more than 6 months old. Information may be outdated. Consider searching for more recent discussions.
mike_mealprep
Member
412
1,890
Jul 2024
Chicago, IL
Nov 18, 2025 at 11:39 AM#1

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

What would genuinely help is knowing what distinguishes the nausea you can titrate through from the nausea that means stop.

Not looking for reassurance. Looking for the part I have got wrong.

36 6mia_MS2, LeilaHI, marcus_mpls and 33 others
Reply Quote Save Share Report
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Nov 18, 2025 at 12:46 PM#2

This one has a reasonably settled answer, so here it is. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

35 5wei_SG, cory_ATX, lori_vegas and 32 others
Reply Quote Save Share Report
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Nov 18, 2025 at 1:53 PM#3
Dr.LipidDallas said:
The line between titrate-through and stop is not severity, it is trajectory and what else is present.

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

34 4FranDenver, Dr.BariatricHTX, LindaRN_retired and 31 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
Nov 18, 2025 at 3:00 PM#4
mike_mealprep said:
The nausea I get is not really nausea, it is an aversion.

Same position here, arrived at the long way round. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

33 3FranDenver, Dr.BariatricHTX, LindaRN_retired and 30 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Nov 18, 2025 at 9:25 PM#5

Clinical perspective, offered as context rather than as advice. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

32 2mike_mealprep, NicoleRaleigh, james_edin and 29 others
Reply Quote Save Share Report
1236

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register